血浆 Epstein-Barr 病毒 DNA 作为鼻咽癌的生物标志物
Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma.
作者信息
Chan K C Allen
机构信息
Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China.
出版信息
Chin J Cancer. 2014 Dec;33(12):598-603. doi: 10.5732/cjc.014.10192. Epub 2014 Nov 21.
Abstract
Nasopharyngeal carcinoma (NPC) is common in southern China and Southeast Asia. Epstein-Barr virus (EBV) infection is an important etiology for NPC, and EBV genome can be detected in almost all tumor tissues of NPC in this region. Plasma EBV DNA, when quantitatively analyzed using real-time polymerase chain reaction (PCR), has been developed as a biomarker for NPC. In this review, the different clinical applications of plasma EBV DNA in the management of NPC, including screening, monitoring, and prognostication, are discussed. In addition, the biological issues of circulating EBV DNA, including the molecular nature and clearance kinetics, are also explored.
摘要
鼻咽癌（NPC）在中国南方和东南亚地区较为常见。爱泼斯坦-巴尔病毒（EBV）感染是NPC的重要病因，该地区几乎所有NPC肿瘤组织中都能检测到EBV基因组。血浆EBV DNA通过实时聚合酶链反应（PCR）进行定量分析，已被开发为NPC的一种生物标志物。在本综述中，讨论了血浆EBV DNA在NPC管理中的不同临床应用，包括筛查、监测和预后评估。此外，还探讨了循环EBV DNA的生物学问题，包括分子性质和清除动力学。
相似文献
1
Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma.
Chin J Cancer. 2014 Dec;33(12):598-603. doi: 10.5732/cjc.014.10192. Epub 2014 Nov 21.
2
Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
Chin Clin Oncol. 2016 Apr;5(2):18. doi: 10.21037/cco.2016.03.07.
3
Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
Cancer. 2014 May 1;120(9):1353-60. doi: 10.1002/cncr.28564. Epub 2014 Jan 29.
4
Clinical applications of plasma Epstein-Barr virus DNA analysis and protocols for the quantitative analysis of the size of circulating Epstein-Barr virus DNA.
Methods Mol Biol. 2006;336:111-21. doi: 10.1385/1-59745-074-X:111.
5
Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
Cancer Sci. 2015 Sep;106(9):1196-201. doi: 10.1111/cas.12718. Epub 2015 Jul 14.
6
Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review.
Methods Mol Biol. 2020;2204:99-107. doi: 10.1007/978-1-0716-0904-0_9.
7
Cell-free Epstein-Barr virus-DNA in patients with nasopharyngeal carcinoma: Plasma versus urine.
Head Neck. 2016 Apr;38 Suppl 1:E1666-73. doi: 10.1002/hed.24297. Epub 2015 Dec 15.
8
[Quantitative and localized detection of Epstein-Barr virus infectious status in nasopharyngeal carcinoma tissue].
Ai Zheng. 2005 Jul;24(7):796-800.
9
Clinical implications of hepatitis B viral infection in Epstein-Barr virus-associated nasopharyngeal carcinoma.
J Clin Virol. 2015 Mar;64:64-71. doi: 10.1016/j.jcv.2014.11.024. Epub 2014 Nov 27.
10
Genome-Wide Analysis of 18 Epstein-Barr Viruses Isolated from Primary Nasopharyngeal Carcinoma Biopsy Specimens.
J Virol. 2017 Aug 10;91(17). doi: 10.1128/JVI.00301-17. Print 2017 Sep 1.
引用本文的文献
1
Research landmarks on the 60th anniversary of Epstein-Barr virus.
Sci China Life Sci. 2025 Feb;68(2):354-380. doi: 10.1007/s11427-024-2766-0. Epub 2024 Nov 4.
2
Salvage endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma in a non-endemic area.
Eur Arch Otorhinolaryngol. 2024 Jul;281(7):3601-3613. doi: 10.1007/s00405-024-08500-8. Epub 2024 Mar 14.
3
Epstein-Barr virus genotype-1 and Mediterranean + strain in gastric cancer biopsies of Ghanaian patients.
Exp Biol Med (Maywood). 2023 Jul;248(14):1221-1228. doi: 10.1177/15353702231181355. Epub 2023 Jul 7.
4
Frequency of Peripheral CD8+ T Cells Expressing Chemo-Attractant Receptors CCR1, 4 and 5 Increases in NPC Patients with EBV Clearance upon Radiotherapy.
Cancers (Basel). 2023 Mar 21;15(6):1887. doi: 10.3390/cancers15061887.
5
Design of InnoPrimers-Duplex Real-Time PCR for Detection and Treatment Response Prediction of EBV-Associated Nasopharyngeal Carcinoma Circulating Genetic Biomarker.
Diagnostics (Basel). 2021 Sep 25;11(10):1761. doi: 10.3390/diagnostics11101761.
6
Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit.
Cancer Immunol Immunother. 2022 Jun;71(6):1531-1543. doi: 10.1007/s00262-021-03075-3. Epub 2021 Oct 18.
7
Establishment and Validation of Nomogram Based on Combination of Pretreatment C-Reactive Protein/Albumin Ratio-EBV DNA Grade in Nasopharyngeal Carcinoma Patients Who Received Concurrent Chemoradiotherapy.
Front Oncol. 2021 Jul 15;11:583283. doi: 10.3389/fonc.2021.583283. eCollection 2021.
8
The Role of Human Papilloma Virus in Dictating Outcomes in Head and Neck Squamous Cell Carcinoma.
Front Mol Biosci. 2021 Jun 23;8:677900. doi: 10.3389/fmolb.2021.677900. eCollection 2021.
9
Geometrically encoded SERS nanobarcodes for the logical detection of nasopharyngeal carcinoma-related progression biomarkers.
Nat Commun. 2021 Jun 8;12(1):3430. doi: 10.1038/s41467-021-23789-3.
10
Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study.
Signal Transduct Target Ther. 2021 Jan 12;6(1):15. doi: 10.1038/s41392-020-00376-4.
本文引用的文献
1
Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing.
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18761-8. doi: 10.1073/pnas.1313995110. Epub 2013 Nov 4.
2
Scanning for cancer genomic changes in plasma: toward an era of personalized blood-based tumor markers.
Clin Chem. 2013 Nov;59(11):1553-5. doi: 10.1373/clinchem.2013.207381. Epub 2013 Jul 10.
3
An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma.
Clin Cancer Res. 2013 Apr 15;19(8):2208-15. doi: 10.1158/1078-0432.CCR-12-3702. Epub 2013 Mar 4.
4
Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program.
Cancer. 2013 May 15;119(10):1838-44. doi: 10.1002/cncr.28001. Epub 2013 Feb 21.
5
Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels.
Cancer. 2013 Mar 1;119(5):963-70. doi: 10.1002/cncr.27853. Epub 2012 Oct 12.
6
Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing.
Clin Chem. 2013 Jan;59(1):211-24. doi: 10.1373/clinchem.2012.196014. Epub 2012 Oct 11.
7
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.
Sci Transl Med. 2012 May 30;4(136):136ra68. doi: 10.1126/scitranslmed.3003726.
8
Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a Western population.
BMC Cancer. 2012 May 30;12:208. doi: 10.1186/1471-2407-12-208.
9
Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma.
Head Neck. 2012 Aug;34(8):1064-70. doi: 10.1002/hed.21890. Epub 2011 Nov 15.
10
Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
Cancer. 2011 Oct 1;117(19):4452-9. doi: 10.1002/cncr.26069. Epub 2011 Mar 22.
Zotero 插件